

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Ortho Regenerative Technologies Inc. (the “Issuer”)**

Trading Symbol: **ORTH**

Number of Outstanding Listed Securities: **24,262,424**

Date: **July 6, 2018**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.
- **The Corporation continues its business objectives as to its pre-clinical development plan and patent prosecution for its four families.**

- **On June 13, 2018 the Corporation announced positive outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. In this study, treatment with Ortho-R was shown to improve healing versus standard of care, with the highest Ortho-R dose having the greatest effect. Treatment with Ortho-R showed improvements in the structural organization of the tendon and the structural appearance of the tendon insertion site. In addition, Clinical signs and histopathology showed no treatment-specific adverse effects, suggesting high safety of Ortho-R.**
2. Provide a general overview and discussion of the activities of management.  
**In the period, Management's primary focus was to (i) continue to raise capital (ii) pursue the activities leading to our pre-clinical development path and manufacturing process (iii) maintain various discussions with well-known contract research organizations for our phase I/II humans' trials.**
  3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.  
**Nothing applicable during the period.**
  4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.  
**Nothing applicable during the period.**
  5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.  
**During the period, the Corporation signed a consulting agreement to retain a third-party consultant to assist the Corporation in identifying and introducing potential business partners for a monthly fee of \$8,000 for a period of 12 months, unless expressly extended by the Parties. After the end of the first 6 months of the term, the Corporation may terminate the Agreement prematurely upon written notice of 30 days.**
  6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.  
**Nothing applicable during the period.**
  7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the

disposition was to a Related Person of the Issuer and provide details of the relationship.

**Nothing applicable during the period.**

8. Describe the acquisition of new customers or loss of customers.

**Nothing applicable during the period.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Nothing applicable during the period.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Nothing applicable during the period.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Nothing applicable during the period.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Nothing applicable during the period.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**N/A**

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
Shares options	200,000	At an exercise price of \$0.50 per share, expiring on December 19, 2019	N/A.

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**No new loans with related parties in the current period**

16. Provide details of any changes in directors, officers or committee members.

**No change in the current period**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**None in the current period.**

### **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 6, 2018

Ortho Regenerative Technologies Inc.  
*/s/ Jo-Anne Mainguy-Piché*  
VP Finance & Chief Financial Officer  
Official Capacity

<b><i>Issuer Details</i></b>	For Month End	Date of Report
Name of Issuer Ortho Regenerative Technologies Inc.	June 2018	YY/MM/D 2018/07/06
Issuer Address 166667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. 514.694.0443	Issuer Telephone No. 514.782.0951
Contact Name Jo-Anne M. Piché	Contact Position VP Finance & CFO	Contact Telephone No. 514.782.0951
Contact Email Address Piche@orthorti.com	Web Site Address www.orthorti.com	